Morepen Laboratories Ltd
Pharmaceuticals & Biotechnology | Small Cap
Morepen Laboratories Ltd demonstrates a mixed financial performance. The company shows exceptional solvency and growth, driven by minimal debt and robust expansion in revenue, profits, and assets. Profitability is also a strong point, with impressive returns on capital, equity, and assets, alongside healthy margins. However, efficiency in asset utilization is a concern, as indicated by lower turnover ratios and longer inventory holding periods. The company's liquidity is reasonable, though there are some weaknesses noted in cash flow management. Furthermore, financial metrics such as earnings per share, book value, and capital expenditure need attention. Overall, Morepen Laboratories exhibits solid financial health, but improvements in operational efficiency and financial management could further enhance its performance.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio2.40
- Profitability Ratio10.00
- Efficiency Ratio4.67
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio7.04
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBearish
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayBullish
- 1 WeekBullish
- 1 MonthNeutral
Morepen Laboratories Ltd demonstrates a mixed financial performance. The company shows exceptional solvency and growth, driven by minimal debt and robust expansion in revenue, profits, and assets. Profitability is also a strong point, with impressive returns on capital, equity, and assets, alongside healthy margins. However, efficiency in asset utilization is a concern, as indicated by lower turnover ratios and longer inventory holding periods. The company's liquidity is reasonable, though there are some weaknesses noted in cash flow management. Furthermore, financial metrics such as earnings per share, book value, and capital expenditure need attention. Overall, Morepen Laboratories exhibits solid financial health, but improvements in operational efficiency and financial management could further enhance its performance.
Overall Valuation Score
P/E RATIO (TTM)
40.91
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
28.61
P/B RATIO
2.17
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
1.46
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
15.78
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹49.5 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company demonstrates excellent growth across various metrics. Revenue, operating profit, EPS, asset, and net income growth rates are all strong, reflecting the company's robust expansion and increasing profitability. This indicates the company is effectively capitalizing on market opportunities and generating significant value for its stakeholders. The consistent positive growth trend suggests a promising outlook for future performance.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 30.22 | -8.34 | 19.18 | 7.22 | -0.33 |
| Operating Profit Growth Rate | 15.13 | -41.61 | 98.75 | 9.43 | -27.59 |
| Earnings Per Share (EPS) Growth | -1.39 | -64.32 | 147.37 | 14.36 | -19.53 |
| Asset Growth Rate | 24.71 | 3.74 | 16.49 | 37.51 | 8.89 |
| Net Income Growth Rate | 5.15 | -61.76 | 148.72 | 21.65 | -18.64 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present some challenges. Adjusted EPS, cash EPS, and book value per share are below expectations, indicating potential areas for improvement in earnings quality and asset valuation. Dividend per share is also low, and capital expenditures are high, suggesting a need to optimize investment strategies and enhance shareholder returns. Addressing these issues could improve the company's financial performance and investor perception.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 2.12 | 0.76 | 1.9 | 2.15 | 1.38 |
| Cash Earnings Per Share (Cash EPS) | 2.71 | 1.31 | 2.55 | 2.67 | 2.4 |
| Book Value Per Share | 12.06 | 14.76 | 16.61 | 21.04 | 22.67 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0.19 | 0.21 |
| Capital Expenditures (CapEx) | 67 | 46 | 81 | 214 | 160 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company exhibits excellent profitability ratios, reflecting its ability to generate profits from its operations and investments. Gross profit margin, ROCE, ROE, ROA, operating margin, and net margin are all strong, indicating efficient cost management and effective revenue generation. This demonstrates the company's capacity to deliver superior returns to its stakeholders and maintain a competitive edge in the industry.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 7.05 | 3.67 | 7.46 | 8 | 4.98 |
| Return on Capital Employed (ROCE) | 23 | 8 | 17 | 15 | 8 |
| Return on Equity (ROE) | 17.62 | 5.18 | 11.45 | 10.2 | 7.7 |
| Return on Assets (ROA) | 12.8 | 7.21 | 12.3 | 9.79 | 6.51 |
| Operating Margin | 8.86 | 5.64 | 9.41 | 9.6 | 6.98 |
| Net Margin | 6.59 | 2.75 | 5.74 | 6.51 | 5.32 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency in utilizing its assets shows mixed performance. While inventory and receivables turnover are at an average level, the fixed asset and capital turnover ratios reveal potential inefficiencies. Longer days sales in inventory and receivable days suggest challenges in managing working capital effectively. These factors indicate that the company may need to optimize its asset utilization to improve overall operational efficiency.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 6.14 | 5.31 | 5.5 | 3.71 | 3.52 |
| Inventory Turnover Ratio | 6.38 | 5.41 | 6.55 | 6.07 | 6 |
| Receivables Turnover Ratio | 7.15 | 5.52 | 5.75 | 5.58 | 5.49 |
| Days Sales in Inventory Ratio | 57.21 | 67.47 | 55.73 | 60.13 | 60.83 |
| Receivable Days | 51.05 | 66.12 | 63.48 | 65.41 | 66.48 |
| Capital Turnover Ratio | 2.67 | 1.88 | 1.99 | 1.5 | 1.3 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company exhibits excellent coverage ratios, indicating a strong ability to meet its interest and dividend obligations. The interest coverage ratio demonstrates that the company can comfortably cover its interest expenses with its earnings. The equity dividend coverage ratio shows a solid capacity to pay dividends to equity shareholders. These factors suggest financial stability and reduced risk for investors.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | -17.14 | 29 | 34.75 | 20.38 | 8.5 |
| Equity Dividend Coverage Ratio | 11.11 | 8.33 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits excellent solvency, with minimal debt and a strong equity base. The debt and debt-to-equity ratios indicate very low levels of financial leverage, reducing the risk of financial distress. A high equity ratio further supports this, demonstrating that the company is primarily financed by equity rather than debt. This provides a stable financial foundation and greater flexibility in navigating economic uncertainties.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 | 0.04 | 0.11 |
| Debt to Equity Ratio | 0 | 0 | 0 | 0.04 | 0.12 |
| Equity Ratio | 1 | 1 | 1 | 0.96 | 0.89 |
| Debt To Asset Ratio | 0 | 0 | 0 | 0.03 | 0.08 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position shows mixed results. Its ability to meet short-term obligations is generally adequate. The quick ratio suggests a strong capacity to cover immediate liabilities with its most liquid assets. However, cash and operating cash flow ratios indicate some challenges in maintaining sufficient cash reserves and generating positive cash flows from operations. This could affect the company's flexibility in handling unforeseen expenses or investment opportunities.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.64 | 2.32 | 2.17 | 2.06 | 2.35 |
| Quick Ratio | 1.08 | 1.68 | 1.6 | 1.53 | 1.85 |
| Cash Ratio | 0.09 | 0.16 | 0.12 | 0.09 | 0.13 |
| Operating Cash Flow Ratio | -0.12 | -0.26 | 0.16 | 0.06 | 0.06 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 33.01 | Overvalued | 58.00 | 6.42 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 25.92 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Lincoln Pharmaceuticals Ltd | 7.31 | 14.01 | Neutral | 98.00 | 43.88 | 88.00 |
| 5 | RPG Life Sciences Ltd | 7.12 | 32.70 | Neutral | 147.00 | 69.64 | 115.00 |
| 6 | Morepen Laboratories Ltd | 7.12 | 28.61 | Neutral | 126.00 | 1.21 | 96.00 |
| 7 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 17.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 9 | Hester Biosciences Ltd | 6.54 | 31.74 | Neutral | 87.00 | 61.24 | 57.00 |
| 10 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 34.77 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Gufic BioSciences Ltd | 5.49 | 55.51 | Neutral | 151.00 | 6.30 | 64.00 |
| 13 | Dishman Carbogen Amcis Ltd | 5.38 | 27.45 | Neutral | 566.00 | -2.45 | 97.00 |
| 14 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 15 | Indoco Remedies Ltd | 5.26 | -22.79 | Neutral | 142.00 | -0.61 | -99.00 |
| 16 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
The management of Morepen Laboratories presents a mixed assessment. The company has demonstrated sales and profit growth over the past decade. However, there's a decline in operating profit margin (OPM) and return on equity (ROE) in recent years. The promoter holding remains relatively stable, indicating continued confidence from the company's leadership. Overall, while the company shows potential, the recent financial trends suggest areas needing focused attention and improvement.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Compounded Sales Growth (10 Years) | 16% | Revenue Expansion |
| Compounded Profit Growth (10 Years) | 49% | Profit growth | |
| CONS | Recent OPM Decline | 9% (Mar 2025) | Operational Efficiency |
| Recent ROE Decline | 12% (Mar 2025) | Shareholder Returns |
Financial Performance & Growth
Morepen Laboratories has shown sales growth over the long term, but recent trends indicate some challenges. Compounded Sales Growth has been 16% over 10 years and 16% over 5 years. However, it has slowed down to 5% over the past 3 years and 7% TTM. Similarly, Compounded Profit Growth has been 49% over 10 years and 29% over 5 years but declines to 5% over the last 3 years and 23% TTM. The quarterly results show fluctuating sales and profit growth, with inconsistent YOY Sales Growth % and YOY Profit Growth %. OPM has varied and stands at 9% in Mar 2025. Overall, while historical growth is strong, recent financial performance shows some volatility.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Sales Growth (%) | 14.3% | 17.1% | 33.1% | -8.36% | 19.25% | 7.17% |
Capital Efficiency & Returns
Morepen Laboratories exhibits mixed capital efficiency and returns. The Return on Capital Employed (ROCE) has fluctuated, with a high of 23% in Mar 2022 but declining to 8% in Mar 2023, before increasing to 15% in Mar 2025. Return on Equity (ROE) has also shown variability, averaging around 13% over 10 years but decreasing to 12% in the last year. The Cash Conversion Cycle (CCC) has generally increased over the years, indicating potentially less efficient working capital management. Overall, the company has demonstrated periods of capital efficiency, recent trends suggest a need for improvement in managing returns and working capital.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE (%) | 4% | 9% | 18.6% | 8% | 17% | 15% |
Financial Health & Prudence
The financial health of Morepen Laboratories presents a mixed assessment. The company has reduced its borrowings over the years, from ₹ 209 Cr in Mar 2014 to ₹ 105 Cr in Mar 2025. The dividend payout has been inconsistent, with no payout until recently.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Borrowings (₹ Cr) | 199 | 148.3 | 18 | 25 | 29 | 105 |
| Dividend Payout (%) | 0% | 0% | 0% | 0% | 0% | 9% |
Strategic & Operational Indicators
Morepen Laboratories shows some signs of strategic initiatives and operational efficiency, but there are areas needing closer attention. Debtor Days have increased from 42 in Mar 2014 to 65 in Mar 2025 indicating longer collection periods. Inventory Days have also risen from 56 to 94 days over the same period, suggesting challenges in inventory turnover. Payable Days have fluctuated. The Cash Conversion Cycle has remained variable, indicating potential inefficiencies in managing working capital. Overall, working capital management needs improvement to enhance operational efficiency.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 53 | 65 | 58 | 68 | 70 | 65 |
| Inventory Days | 54 | 70 | 90 | 87 | 85 | 94 |
| Payable Days | 127 | 141 | 102 | 87 | 101 | 114 |
The risk assessment for Morepen Laboratories is rated Orange, indicating moderate risk. The company exhibits segment performance volatility reflected in fluctuating quarterly sales and profit growth. Foreign exchange or interest rate exposure are not explicitly detailed, but the presence of borrowings and international sales suggests potential exposure. Overall, the identified risks suggest a need for cautious monitoring and proactive risk management strategies.
Segment performance volatility
Morepen Laboratories experiences segment performance volatility, as reflected in its fluctuating quarterly results. YOY Sales Growth % and YOY Profit Growth % have varied significantly across different quarters, indicating inconsistency in financial performance. This variability suggests potential risks in relying on specific segments for stable revenue and profit generation.
Foreign exchange or interest rate exposure
While specific details on foreign exchange or interest rate exposure are not explicitly provided, Morepen Laboratories likely faces these risks due to its borrowings and international sales. Fluctuations in exchange rates could impact revenue and profitability from international markets, while changes in interest rates could affect the cost of borrowings. These exposures require monitoring.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1050.30Bearish
- SMA 2050.97Bearish
- SMA 5050.61Bearish
- EMA 1050.23Bearish
- EMA 2050.64Bearish
- EMA 5050.20Bearish
- DEMA 1049.67Bullish
- DEMA 2050.28Bearish
- DEMA 5051.68Bearish
- TEMA 1049.52Bullish
- TEMA 2049.57Bullish
- TEMA 5051.31Bearish
- MACD-0.34Bearish
- ADX30.91Strong Trend
- IndicatorValueSignal
- RSI36.50Neutral
- CCI-115.07Oversold
- ROC 9-1.97Bearish
- ROC 14-3.19Bearish
- ROC 25-4.51Bearish
- Stoch K21.65Neutral
- Stoch D13.32Oversold
- IndicatorValueSignal
- BB Upper52.63Neutral
- BB Middle50.97Neutral
- BB Lower49.30Neutral
- ATR0.75Low Volatility
- IndicatorValueSignal
- MFI34.03Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1050.70Bearish
- SMA 2051.38Bearish
- SMA 5048.54Bullish
- EMA 1050.49Bearish
- EMA 2050.52Bearish
- EMA 5049.00Bullish
- DEMA 1050.01Bearish
- DEMA 2051.12Bearish
- DEMA 5051.47Bearish
- TEMA 1049.48Bullish
- TEMA 2050.34Bearish
- TEMA 5052.04Bearish
- MACD0.30Bearish
- ADX29.39Strong Trend
- IndicatorValueSignal
- RSI45.50Neutral
- CCI-135.18Oversold
- ROC 9-3.64Bearish
- ROC 14-4.14Bearish
- ROC 255.34Bullish
- Stoch K17.87Oversold
- Stoch D12.54Oversold
- IndicatorValueSignal
- BB Upper53.20Neutral
- BB Middle51.37Neutral
- BB Lower49.55Neutral
- ATR1.02Low Volatility
- IndicatorValueSignal
- MFI35.75Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1051.35Bearish
- SMA 2049.55Bullish
- SMA 5045.95Bullish
- EMA 1050.49Bearish
- EMA 2049.51Bullish
- EMA 5046.97Bullish
- DEMA 1051.02Bearish
- DEMA 2051.56Bearish
- DEMA 5050.17Bearish
- TEMA 1050.31Bearish
- TEMA 2051.72Bearish
- TEMA 50N/AN/A
- MACD1.45Bearish
- ADX38.53Strong Trend
- IndicatorValueSignal
- RSI54.70Neutral
- CCI-3.28Neutral
- ROC 9-4.20Bearish
- ROC 141.16Bullish
- ROC 2511.42Bullish
- Stoch K48.41Neutral
- Stoch D56.73Neutral
- IndicatorValueSignal
- BB Upper54.74Neutral
- BB Middle49.55Neutral
- BB Lower44.36Neutral
- ATR1.71Low Volatility
- IndicatorValueSignal
- MFI51.83Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1049.50Bearish
- SMA 2046.87Bullish
- SMA 5044.09Bullish
- SMA 10041.33Bullish
- SMA 20043.49Bullish
- EMA 1049.47Bullish
- EMA 2047.65Bullish
- EMA 5044.78Bullish
- EMA 10043.48Bullish
- EMA 20045.19Bullish
- DEMA 1051.39Bearish
- DEMA 2050.47Bearish
- DEMA 5047.71Bullish
- DEMA 10043.62Bullish
- DEMA 20040.32Bullish
- TEMA 1051.50Bearish
- TEMA 2051.48Bearish
- TEMA 5049.86Bearish
- TEMA 10047.05Bullish
- TEMA 20040.30Bullish
- MACD2.20Bullish
- ADX30.58Strong Trend
- IndicatorValueSignal
- RSI58.23Neutral
- CCI65.04Neutral
- ROC 146.43Bullish
- ROC 2515.09Bullish
- Stoch K73.38Neutral
- Stoch D80.83Overbought
- IndicatorValueSignal
- BB Upper53.62Neutral
- BB Middle46.87Neutral
- BB Lower40.12Neutral
- ATR2.62High Volatility
- IndicatorValueSignal
- MFI77.40Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 2040.81Bullish
- SMA 5045.26Bullish
- EMA 2042.59Bullish
- EMA 5045.55Bullish
- DEMA 2042.55Bullish
- DEMA 5039.95Bullish
- TEMA 2045.36Bullish
- TEMA 5037.85Bullish
- MACD0.38Bullish
- ADX17.78Weak Trend
- IndicatorValueSignal
- RSI56.80Neutral
- CCI30.96Neutral
- ROC 1425.96Bullish
- ROC 2522.69Bullish
- Stoch K73.55Neutral
- Stoch D66.22Neutral
- IndicatorValueSignal
- BB Upper47.71Overbought
- BB Middle40.81Neutral
- BB Lower33.92Neutral
- ATR4.71High Volatility
- IndicatorValueSignal
- MFI78.03Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 639.89Bullish
- SMA 1245.42Bearish
- SMA 2456.12Bearish
- EMA 641.74Bullish
- EMA 1245.11Bearish
- EMA 2448.34Bearish
- DEMA 639.52Bullish
- DEMA 1239.41Bullish
- DEMA 2446.59Bearish
- TEMA 641.15Bullish
- TEMA 1236.81Bullish
- TEMA 2440.79Bullish
- MACD1.55Bearish
- ADX16.73Weak Trend
- IndicatorValueSignal
- RSI49.36Neutral
- CCI-17.48Neutral
- ROC 25-13.61Bearish
- ROC 5018.30Bullish
- Stoch K19.56Oversold
- Stoch D42.19Neutral
- IndicatorValueSignal
- BB Upper81.03Neutral
- BB Middle53.31Neutral
- BB Lower25.59Neutral
- ATR11.41Low Volatility
- IndicatorValueSignal
- MFI68.28Neutral